文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

羟氯喹与低剂量泼尼松治疗未分化结缔组织病复发性流产的三臂多中心开放标签随机对照试验:ILIFE试验方案

A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial.
PubMed 文献 · Trials · 2020-09-09

未分化结缔组织病(UCTD)可致不良妊娠结局及复发性流产(RSA),抗凝可预防妊娠并发症,但加用免疫抑制剂能否预防流产尚不明确。ILIFE试验为三臂多中心开放标签随机对照试验,计划纳入426例UCTD合并RSA患者,按1:1:1随机分配,主要比较羟氯喹联合低剂量泼尼松加抗凝与单用抗凝,第三臂为羟氯喹联合抗凝作次要比较,主要结局为活产率。

要点

  • UCTD合并复发性流产患者,在抗凝基础上加用羟氯喹和低剂量泼尼松可能改善妊娠结局。
  • 该试验为三臂设计,同时评估免疫抑制剂对UCTD疾病进展的影响。
  • 主要结局为活产率,次要结局包括不良妊娠结局和UCTD进展。

核心结论

  • 该试验将评估在抗凝基础上加用羟氯喹和低剂量泼尼松能否预防UCTD合并RSA患者的妊娠丢失。
  • 该研究为首个评估免疫抑制方案对UCTD患者妊娠结局及疾病进展影响的多中心开放标签随机对照试验。

研究设计与样本

  • 三臂、多中心、开放标签随机对照试验,计划纳入426例符合条件的UCTD合并复发性流产患者。
  • 患者按1:1:1随机分配至三个治疗臂:羟氯喹联合低剂量泼尼松加抗凝、单用抗凝、羟氯喹联合抗凝。
  • 主要目的为比较羟氯喹联合低剂量泼尼松加抗凝与单用抗凝的疗效,第三臂用于次要比较。
  • 试验注册号ClinicalTrials.gov NCT03671174,注册日期2018年9月14日。

临床怎么用

  • 该试验结果将为UCTD合并复发性流产患者是否在抗凝基础上加用免疫抑制剂提供证据。

局限性

  • 研究为开放标签设计,患者和研究者知晓分组,可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressants to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD. METHODS: The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD. DISCUSSION: This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease. TRIAL REGISTRATION: ClinicalTrials.gov NCT03671174 . Registered on 14 September 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yang S, Ni R, Lu Y, et al. A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone to treat recurrent pregnancy loss in women with undifferentiated connective tissue diseases: protocol for the Immunosuppressant regimens for LIving FEtuses (ILIFE) trial. Trials. 2020. PMID: 32907619. doi:10.1186/s13063-020-04716-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。